R
Ronaldo Damião
Researcher at Rio de Janeiro State University
Publications - 80
Citations - 4976
Ronaldo Damião is an academic researcher from Rio de Janeiro State University. The author has contributed to research in topics: Denosumab & Prostate cancer. The author has an hindex of 23, co-authored 77 publications receiving 4513 citations. Previous affiliations of Ronaldo Damião include Sao Paulo State University.
Papers
More filters
Journal ArticleDOI
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi,Michael A. Carducci,Matthew R. Smith,Ronaldo Damião,Janet E. Brown,Lawrence Karsh,Piotr Milecki,Neal D. Shore,Michael Rader,H. Wang,Qi Jiang,Sylvia Tadros,Roger Dansey,Carsten Goessl +13 more
TL;DR: Denosumab was better than zoledronic acid for prevention of skeletal-related events, and potentially represents a novel treatment option in men with bone metastases from castration-resistant prostate cancer.
Journal ArticleDOI
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer : results of a phase 3, randomised, placebo-controlled trial.
Matthew R. Smith,Fred Saad,Robert E. Coleman,Neal D. Shore,Karim Fizazi,Bertrand Tombal,Kurt Miller,Paul Sieber,Lawrence Karsh,Ronaldo Damião,Teuvo L.J. Tammela,Blair Egerdie,Hendrik Van Poppel,Joseph L. Chin,Juan Morote,Francisco Gomez-Veiga,Tomasz Borkowski,Zhishen Ye,Amy Kupic,Roger Dansey,Carsten Goessl +20 more
TL;DR: This large randomised study shows that targeting of the bone microenvironment can delay bone metastasis in men with prostate cancer and significantly increased bone-metastasis-free survival.
Journal ArticleDOI
The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study
Claus G. Roehrborn,Paul Siami,Jack Barkin,Ronaldo Damião,Kim Major-Walker,Indrani Nandy,Betsy Morrill,R. Paul Gagnier,Francesco Montorsi +8 more
TL;DR: The 4-yr CombAT data provide support for the long-term use of dutasteride and tamsulosin combination therapy in men with moderate-to-severe LUTS due to BPH and prostatic enlargement.
Journal ArticleDOI
The Effects of Dutasteride, Tamsulosin and Combination Therapy on Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia and Prostatic Enlargement: 2-Year Results From the CombAT Study
Claus G. Roehrborn,Paul Siami,Jack Barkin,Ronaldo Damião,Kim Major-Walker,Betsy Morrill,Francesco Montorsi +6 more
TL;DR: In men with moderate to severe lower urinary tract symptoms and prostate enlargement (30 cc or greater) combination therapy provides a significantly greater degree of benefit than tamsulosin or dutasteride monotherapy.
Journal ArticleDOI
Denosumab and Bone Metastasis–Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time
Matthew R. Smith,Fred Saad,Stéphane Oudard,Neal D. Shore,Karim Fizazi,Paul Sieber,Bertrand Tombal,Ronaldo Damião,Gavin Marx,Kurt Miller,Peter J. Van Veldhuizen,Juan Morote,Zhishen Ye,Roger Dansey,Carsten Goessl +14 more
TL;DR: Denosumab consistently improves bone metastasis-free survival in men with shorter PSADT and seems to have the greatest treatment effects in men at high risk for progression.